Free tool
FAERS Monitor: Nyvepria
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761111 or its brand name (Nyvepria, Pegfilgrastim-Apgf). Reports on generic versions are filed under their own applications.
Reports
198
Serious
118
60% of reports
Hospitalization
68
Death reported
22
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death23
- off label use17
- pyrexia15
- drug dose omission by device12
- device leakage11
- nausea11
- fatigue10
- asthenia9
- diarrhoea7
- neutropenia7
- device issue6
- device operational issue6
- hospitalisation6
- decreased appetite5
- dyspepsia5
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2021 | 3 |
| 2022 | 17 |
| 2023 | 35 |
| 2024 | 53 |
| 2025 | 67 |
| 2026 | 23 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,961 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| device operational issueSignal | 6 | 148.4 | 67.4 | 736 |
| device leakageSignal | 11 | 27.0 | 15.2 | 250 |
| drug dose omission by deviceSignal | 12 | 16.3 | 9.4 | 158 |
| device issueSignal | 6 | 7.1 | 3.2 | 26 |
| neutropeniaSignal | 7 | 5.5 | 2.6 | 21 |
| dyspepsiaSignal | 5 | 5.4 | 2.3 | 14 |
| pyrexiaSignal | 15 | 4.6 | 2.8 | 39 |
| hospitalisationSignal | 6 | 4.1 | 1.9 | 11 |
| deathSignal | 23 | 2.8 | 1.9 | 27 |
| astheniaSignal | 9 | 2.5 | 1.3 | 7 |
| decreased appetite | 5 | 2.3 | 1.0 | 2 |
| off label useSignal | 17 | 2.1 | 1.3 | 9 |
| nausea | 11 | 1.5 | 0.8 | 1 |
| fatigue | 10 | 1.4 | 0.7 | 1 |
| diarrhoea | 7 | 1.2 | 0.6 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.